PUBLISHER: FirstWord Group | PRODUCT CODE: 1507967
PUBLISHER: FirstWord Group | PRODUCT CODE: 1507967
Multiple Myeloma - KOL Insight
The Multiple Myeloma (MM) landscape is rapidly evolving with significant advancements in therapeutic options. Insights from leading KOLs provide a comprehensive review of the current and future treatment landscape for MM, highlighting the consolidation of Darzalex in quadruplet regimens for newly diagnosed patients, the recent approval of Abecma and Carvykti for earlier treatment lines, the potential of BCMA-targeting bispecific antibodies like Tecvayli and Elrexfio, and the emerging role of Talvey for patients relapsing on BCMA-targeting therapies. Explore the evolving MM treatment algorithm and the implications for clinical practice and drug development.
Table of Contents
Executive summary (1)
Current and future treatment algorithm
Research objectives
Monoclonal antibodies (mAbs) (32)
- Approved drugs (32)
- Darzalex (daratumumab; J&J) (14)
- Sarclisa (isatuximab; Sanofi) (18)
Immunomodulatory drugs (IMiDs) (8)
- Pipeline drugs (8)
- Iberdomide (CC-220; BMS) and mezigdomide (CC-92480; BMS) (8)
Bcl-2 inhibitors (14)
- Pipeline drugs (14)
- Venetoclax (Venclexta/Venclyxto; AbbVie/Roche) (14)
CAR T-cell therapies (36)
- Approved therapies (26)
- Abecma (idecabtagene vicleucel; BMS/2seventy bio) and Carvykti (ciltacabtagene autoleucel; J&J/Legend) (26)
- Pipeline therapies (10)
- Anitocabtagene autoleucel (CART-ddBCMA; Gilead/Arcellx); zevorcabtagene autoleucel (CARsgen); durcabtagene autoleucel (PHE885; Novartis); BMS-986393 (CC-95266; BMS) (10)
Bispecific antibodies (64)
- Approved drugs (42)
- BCMA-targeting: Tecvayli (teclistamab; J&J) and Elrexfio (elranatamab; Pfizer) (27)
- GPRC5D-targeting: Talvey (talquetamab; J&J) (15)
- Pipeline drugs (22)
- BMCA-targeting: linvoseltamab (REGN5458; Regeneron); ABBV-383 (AbbVie); alnuctamab (BMS) (13)
- FcRH5-targeting: cevostamab (Roche) (9)
Antibody-drug conjugates (ADCs) (13)
- Pipeline drugs (13)
- Blenrep (belantamab mafodotin; GSK) (13)
Future treatment trends (10)
- Key insights summary (10)
Appendix (4)
- KOL details (4)
- KOLs from the USA (3)
- KOLs from Europe (1)
KOL Bulletins (1)
